_Market.jpg)
The global Peptide CDMO (Pharmaceutical) market size was accounted at USD 2028.60 Mn in 2021; It is projected to grow at a compound annual growth rate (CAGR) of 9.0% from 2022 to 2030. The Global peptide CDMO (Pharmaceutical) market size was valued at US$ 2028.60 million in 2021 and is expected to grow at a compound annual growth rate (CAGR) of 9.0% from 2022 to 2030. Peptides are bioactive molecules that bind to specific cell surface receptors, such as G protein-coupled receptors (GPCRs) or ion channels, where they trigger intracellular effects. Peptides have characteristics like safety, high specificity, and targeted drug delivery which are expected to create the future potential of expanding peptide therapeutics business. Increasing clinical demand for peptides favours the business of CDMOs.
Major driving factors of the peptide CDMO (pharmaceutical) market are the growing clinical applications of peptides, advancements in medical technologies, surging investments by pharma companies in peptides to develop drug therapies, increasing cases of chronic diseases, and a growing number of health-conscious people. Several drug developing industries outsource their peptide production operations to CDMOs (contract research, development and manufacturing organization) to achieve better operational efficiency and flexibility, which is projected to propel the growth of the peptide CDMO (pharmaceutical) market in the coming years. However, the high cost of outsourced services and the need for specialized expertise for peptide production may restrict the market growth during the projected period.
The peptide CDMO (pharmaceutical) market is segmented based on the scale of operation, method used, applications, synthesis types, and region. The scale of operation segment comprises preclinical/clinical and commercial. By method used, the market is classified into chemical synthesis method and non-chemical synthesis method. The market is segmented into peptide supplements, peptide vaccines, peptides as radio-theranostic agents, cell-penetrating peptides (CPPs), affinity ligands, and protein mimics based on applications. The market is divided into LPPS (Liquid-phase Peptide Synthesis), SPPS (Solid-phase Peptide Synthesis), and Mixed Phase by synthesis types. SPPS segment is expected to dominate this market over the forecast period. Region-wise, the market is studied across North America, Europe, Asia-Pacific, Latin America, & the Middle East and Africa.
Asia-Pacific is expected to witness the fastest growth in the next few years due to the rising applications of peptides, increasing government initiatives in the R&D of peptide-based products & treatments, and the high prevalence of chronic diseases. Some of the key players operating in the peptide CDMO (pharmaceutical) market are AmbioPharm, Auspep, Bachem, BCN Peptide, CPC Scientific, CBL- Chemical and Biopharmaceutical Laboratories, Creative Peptides, Chinese Peptide, CSBio, Corden Pharma, PolyPeptide, Hybio Pharmaceutical, Peptide Institute, Pepscan, Almac, Vivitide, CreoSalus Inc, ScinoPharm, Senn Chemicals, Wuxi AppTec, Olon, Belyntic, Ferring Pharma, Numaferm, Hybio Pharmaceutical, Provepharm Life Solutions, Enzene Biosciences, Ardena Holding, Stelis Biopharma, Piramal Pharma, Space Peptides Pharmaceutical, and others.
